VESIcare is a competitive muscarinic receptor antagonist

Antimuscarinics play an important role in blocking several major cholinergically mediated functions. They block the muscarinic receptors in the urinary bladder smooth muscles, reducing contractions of these muscles.1

NEXT: Dosing

VESIcare offers flexible dosing1

The recommended dose is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily. VESlcare should be taken with water and swallowed whole, with or without food.

tablet medication
5 mg 10 mg

water drop

VESIcare should be taken with water and swallowed whole. The tablets can be administered with or without food.

90-day supply

Prescribing a 90-day supply of VESIcare may offer patients less out-of-pocket cost* and fewer visits to the pharmacy.

*Subject to plan provision.

dispense as written


Since VESIcare has no generic equivalent, be sure to include "dispense as written" on your scripts to ensure patients receive VESIcare.

NEXT: Efficacy

Indication and Dosage

VESIcare® (solifenacin succinate) tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily.

Important Safety Information

VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product.

Angioedema of the face, lips, tongue and/or larynx have been reported with VESIcare. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, VESIcare should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided. Anaphylactic reactions have been reported rarely in patients treated with VESIcare. VESIcare should not be used in patients with a known or suspected hypersensitivity to solifenacin succinate. In patients who develop anaphylactic reactions, VESIcare should be discontinued and appropriate therapy and/or measures should be taken.

VESIcare should be administered with caution to patients with clinically significant bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal or hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended.

Anticholinergic central nervous system (CNS) effects have been reported with VESIcare use, including headache, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing dose, and be advised not to drive or operate heavy machinery until they know how VESIcare affects them. If a patient experiences these effects, dose reduction or drug discontinuation should be considered.

In placebo-controlled studies, for the 10-mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction, and one intestinal obstruction). For the 5‑mg dose, one serious adverse event (angioneurotic edema) was reported.

In placebo-controlled studies, the most common adverse reactions reported by patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and urinary tract infection (2.8%, 4.8%, 2.8%) with VESIcare 5 mg, 10 mg, and placebo, respectively.

Please click here for complete Prescribing Information.


  1. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006;60(8):959-66. Erratum in: Int J Clin Pract 2006;60(11):1517-8.
  2. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148(5):565-78.
  3. Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45(3):253-308.
  4. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350(8):786-99.
  5. VESIcare® [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.


  1. VESIcare® [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.

You are now leaving

You are now leaving The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
Continue to Twitter.
As always, the information you give us will not be sold or shared with anyone. Please see our Privacy Policy for more information.

For healthcare professionals only

The information contained on this site is intended for healthcare professionals in the United States only. It is not intended for the general public.